Literature DB >> 15673726

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.

Po-Ren Hsueh1, Yeu-Jun Lau, Yin-Ching Chuang, Jen-Hsien Wan, Wen-Kuei Huang, Jainn-Ming Shyr, Jing-Jou Yan, Kwok-Woon Yu, Jiunn-Jong Wu, Wen-Chien Ko, Yi-Chueh Yang, Yung-Ching Liu, Lee-Jene Teng, Cheng-Yi Liu, Kwen-Tay Luh.   

Abstract

The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 microg/ml, and for all other Candida species isolates, voriconazole MICs were </=0.5 microg/ml. The proportions of isolates for which amphotericin B MICs were >/=2 microg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were >/=16 microg/ml, and two (3%) isolates were not inhibited by 1 mug of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 microg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 microg/ml) and 90% (2 microg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by </=1 microg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673726      PMCID: PMC547329          DOI: 10.1128/AAC.49.2.512-517.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

2.  Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Pan-Chyr Yang; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431

3.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

Authors:  D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Authors:  M S Saag; R J Graybill; R A Larsen; P G Pappas; J R Perfect; W G Powderly; J D Sobel; W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

5.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Guillermo Garcia-Effron; Emilia Mellado; Araceli Monzon; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years.

Authors:  Yee-Chun Chen; Shan-Chwen Chang; Kwen-Tay Luh; Wei-Chuan Hsieh
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

10.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  23 in total

1.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

5.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

6.  In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Mechanisms of azole resistance in a clinical isolate of Candida tropicalis.

Authors:  Patrick Vandeputte; Gérald Larcher; Thierry Bergès; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 8.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

9.  In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

Authors:  Sheng-Yuan Ruan; Chen-Chen Chu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.